Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

246.60 -2.76 (-1.10%)

Streaming Delayed Price Updated: 12:35 PM EDT, Aug 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ascendis Pharma A/S - Ordinary Share

Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients

August 18, 2026

From Eyconis Inc.

Via GlobeNewswire

3 Oversold Stocks with Big RSI Rebound Potential

October 03, 2024

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

Via MarketBeat

Topics Economy

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 03, 2024

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 05, 2023

From Royalty Pharma plc

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm

June 30, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm

June 25, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S ↗

June 20, 2023

San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors.

Via SBWire

Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm

June 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm

April 28, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S ↗

April 17, 2023

San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

April 14, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm

April 07, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation

April 04, 2023

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

April 04, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm

April 03, 2023

From The Schall Law Firm

Via Business Wire

ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND

April 03, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

Johnson & Johnson: Taking The Bull By The Horns?

February 21, 2023

Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.

Via MarketBeat

Topics Intellectual Property Regulatory Compliance

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.